Alpha Cognition Stock Price, News & Analysis

Alpha Cognition (Nasdaq: ACOG) will present new clinical data on cholinesterase inhibitors and ZUNVEYL® (benzgalantamine) at two scientific meetings in late 2025. The company will present poster sessions at the ASCP Annual Meeting (Oct 23–25, 2025) and the NEI Annual Congress (Nov 6–9, 2025).

Accepted posters cover AChEI topics including persistence of therapy, switching methodologies, interactions with psychotropic medications, and literature reviews on effects on mortality and sleep in Alzheimer’s disease and related dementias.

The company says ZUNVEYL is an enteric-coated prodrug designed to combine cholinesterase inhibition with nicotinic receptor modulation to improve treatment continuity.

Alpha Cognition (Nasdaq: ACOG) will present new clinical data at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025.

On October 24, 2025 the company will present three posters: Poster 12 — Acetylcholinesterase Inhibitors and Psychotropic Medication Use in ADRD; Poster 3 — Persistence of Therapy in ADRD; and Poster 4 — Evidence-Based Approaches to Switching AChEIs in Alzheimer’s Disease. Presentations include insights on cholinesterase inhibitors and ZUNVEYL (benzgalantamine) aimed at updating evidence-based guidance for clinicians treating older adults with neurodegenerative disease.

Alpha Cognition (Nasdaq: ACOG) has announced the pricing of its oversubscribed public offering of 5.6 million common shares at $6.25 per share, raising approximately $35 million in gross proceeds. The offering includes a 30-day over-allotment option for an additional 840,000 shares.

The company's total cash position is expected to reach $70 million post-closing. The proceeds will fund the commercial launch acceleration of ZUNVEYL® (Benzgalantamine), focusing on sales expansion, marketing investment, and enhancing payer coverage and reimbursement infrastructure in the Alzheimer's treatment market.

The offering, led by Titan Partners Group, is expected to close around October 2, 2025, with strong participation from both existing shareholders and a premier healthcare-dedicated investor.

Alpha Cognition (NASDAQ:ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced a proposed underwritten public offering of common shares and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to 15% additional common shares.

The net proceeds will be used to accelerate commercial launch activities, including sales expansion, marketing investment, and enhancing payer coverage infrastructure in the Alzheimer's treatment landscape. Titan Partners Group is acting as the sole bookrunner for this offering, which will be made under the company's effective S-3 shelf registration.

Alpha Cognition (Nasdaq: ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative disease treatments, has announced its upcoming participation in two major healthcare investor conferences in September 2025.

CEO Michael McFadden will present at the Cantor Global Healthcare Conference on September 5 at 7:00 a.m. ET and the H.C. Wainwright & Co. Healthcare Conference on September 9 at 2:00 p.m. ET. Presentation transcripts will be available on the company's website for 30 days following the events.

Alpha Cognition (NASDAQ:ACOG) reported significant progress in Q2 2025, marking its first full quarter of ZUNVEYL® commercialization. The company achieved ~$2M YTD net product revenue, with the drug being ordered in over 300 long-term care facilities and maintaining a 65% repeat order rate.

Key developments include securing a national Medicare Part D contract without prior authorization requirements, and China Medical System's New Drug Application (NDA) acceptance by NMPA. Additionally, the company completed a Department of Defense-funded Bomb Blast study demonstrating ALPHA-1062's efficacy in reducing neuroinflammation and toxic Tau proteins in mild traumatic brain injury (mTBI).

Alpha Cognition (NASDAQ:ACOG) reported Q2 2025 financial results and operational updates, highlighting the successful launch of ZUNVEYL with $2 million in net product revenues year-to-date, including $1.6 million in Q2. The company's sales team has engaged with over 3,700 healthcare professionals and generated prescriptions in more than 300 nursing homes.

The company secured its first national Medicare Part D contract without prior authorization requirements. Additionally, ACOG completed a pre-clinical Bomb Blast study for ALPHA-1062 with the U.S. Department of Defense, showing reduced neuroinflammation and neuropathology associated with blast trauma.

Financial position remains strong with $39.4 million in cash as of June 30, 2025, providing an estimated two-year runway at current utilization rates. The company reported a Q2 net loss of $10.5 million, including a $5.2 million non-cash warrant liability adjustment.

Alpha Cognition (Nasdaq: ACOG), a biopharmaceutical company focused on neurodegenerative disease treatments, will release its Q2 2025 financial results on August 14, 2025 after market close.

The company will host a conference call to discuss the results, with management providing a detailed review of financial performance and operational updates. Investors can access the call through various channels, including telephone dial-in and a live audio webcast.

Alpha Cognition (Nasdaq: ACOG) announced that its partner China Medical System Holdings Limited (CMS) has received acceptance of the New Drug Application (NDA) for ZUNVEYL® (Benzgalantamine) by China's National Medical Products Administration (NMPA) for review. The application is for treating mild-to-moderate Alzheimer's dementia.

The company stands to receive regulatory and sales milestones, plus royalties upon ZUNVEYL's approval in China and other Asian territories. According to Lancet Public Health, there are approximately 7.93 million patients with mild-to-moderate Alzheimer's dementia in China, with numbers expected to rise due to aging population trends.